BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11200501)

  • 1. The 9-position in berberine analogs is an important determinant of DNA topoisomerase II inhibition.
    Krishnan P; Bastow KF
    Anticancer Drug Des; 2000 Aug; 15(4):255-64. PubMed ID: 11200501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
    Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
    Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
    Marx G; Zhou H; Graves DE; Osheroff N
    Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives.
    Bailly C; Dassonneville L; Carrasco C; Lucas D; Kumar A; Boykin DW; Wilson WD
    Anticancer Drug Des; 1999 Feb; 14(1):47-60. PubMed ID: 10363027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)].
    Vashisht Gopal YN; Konuru N; Kondapi AK
    Arch Biochem Biophys; 2002 May; 401(1):53-62. PubMed ID: 12054487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
    René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
    Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minor groove-directed and intercalative ligand-DNA interactions in the poisoning of human DNA topoisomerase I by protoberberine analogs.
    Pilch DS; Yu C; Makhey D; LaVoie EJ; Srinivasan AR; Olson WK; Sauers RR; Breslauer KJ; Geacintov NE; Liu LF
    Biochemistry; 1997 Oct; 36(41):12542-53. PubMed ID: 9376359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cationic porphyrins and analogues as new DNA topoisomerase I and II inhibitors.
    Shuai L; Wang S; Zhang L; Fu B; Zhou X
    Chem Biodivers; 2009 Jun; 6(6):827-37. PubMed ID: 19551725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
    Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
    Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
    Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
    Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of pyrrolo[1,2-alpha]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation.
    Skibo EB; Gordon S; Bess L; Boruah R; Heileman MJ
    J Med Chem; 1997 Apr; 40(9):1327-39. PubMed ID: 9135030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
    De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
    Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and topoisomerase II inhibition activity of 4'-demethylepipodophyllotoxin-lexitropsin conjugates.
    Gupta R; al-Said NH; Oreski B; Lown JW
    Anticancer Drug Des; 1996 Jun; 11(4):325-38. PubMed ID: 8679055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, GC selective DNA binding and topoisomerase II inhibition activities of ruthenium(II) polypyridyl complex containing 11-aminopteridino[6,7-f][1,10]phenanthrolin-13(12H)-one.
    Gao F; Chao H; Zhou F; Chen X; Wei YF; Ji LN
    J Inorg Biochem; 2008; 102(5-6):1050-9. PubMed ID: 18295337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene.
    Vashisht Gopal YN; Jayaraju D; Kondapi AK
    Arch Biochem Biophys; 2000 Apr; 376(1):229-35. PubMed ID: 10729210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells.
    Snyder RD
    Environ Mol Mutagen; 2000; 35(1):13-21. PubMed ID: 10692223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.
    Hasinoff BB; Wu X; Begleiter A; Guziec LJ; Guziec F; Giorgianni A; Yang S; Jiang Y; Yalowich JC
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):221-33. PubMed ID: 16010589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin.
    Montaner B; Castillo-Avila W; Martinell M; Ollinger R; Aymami J; Giralt E; Pérez-Tomás R
    Toxicol Sci; 2005 Jun; 85(2):870-9. PubMed ID: 15788728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.
    Hsiang YH; Jiang JB; Liu LF
    Mol Pharmacol; 1989 Sep; 36(3):371-6. PubMed ID: 2550774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.